INTERIM ANALYSIS OF PHASE III STUDY SHOWS TAXOTERE® (docetaxel)- BASED CHEMOTHERAPY REGIMENS COMBINED WITH HERCEPTIN® (trastuzumab) SIGNIFICANTLY IMPROVED DISEASE FREE SURVIVAL IN EARLY-STAGE HER2-POSITIVE BREAST CANCER